Literature DB >> 34191198

New criteria for evaluation of electroretinogram in patients with retinitis pigmentosa.

Hamideh Sabbaghi1, Soroor Behbahani2, Narsis Daftarian3, Hamid Ahmadieh4.   

Abstract

BACKGROUND: Electroretinogram (ERG) plays an essential role in the diagnosis of retinal disease. Choosing appropriate methods could extract valuable information from ERG. In this study, a new criterion based on time-frequency domain analysis was proposed to investigate the retina in retinitis pigmentosa (RP) patients.
MATERIALS AND METHODS: The total number of 16 eyes from eight RP patients and 20 eyes from age-matched healthy subjects were assessed. The signals included photopic and scotopic ERGs. Continuous wavelet transform was applied to ERGs. Dominant frequencies were extracted, and the contours related to these dominant frequencies were selected. As a new criterion, the areas related to dominant frequency contours were considered a feature to differentiate the RP and normal groups. To better evaluate the proposed criterion results, the time-domain analysis characteristics of ERG were also considered.
RESULTS: The results showed an increase in implicit time and reduced amplitude in RP patients (P < 0.05). A significant decrease of dominant frequencies and increasing their occurrence time were seen in ERG of RP patients. Also, in RP patients, the third dominant frequency was disappeared from the three main frequencies observed in photopic ERGs of normal subjects. The area criterion showed a significant decrease in RP groups (P < 0.05).
CONCLUSION: RP can cause changes in the time and time-frequency components of the ERG. The area index could represent a new view of the characteristics of the ERG in the time-frequency domain. This criterion can help the ophthalmologist to have a better evaluation of retinal disease.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Area index; Continuous wavelet transform; Dominant frequency; Electroretinogram; Retinitis pigmentosa

Mesh:

Year:  2021        PMID: 34191198     DOI: 10.1007/s10633-021-09843-x

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  35 in total

1.  Time and frequency components of ERG responses in retinitis pigmentosa.

Authors:  Samira Ebdali; Bijan Hashemi; Hassan Hashemi; Ebrahim Jafarzadehpur; Soheila Asgari
Journal:  Int Ophthalmol       Date:  2017-11-30       Impact factor: 2.031

2.  [Clinical aspects, diagnosis, and treatment of retroperitoneal teratoid tumors in children].

Authors:  A F Bukhny
Journal:  Khirurgiia (Mosk)       Date:  1969-07

3.  A novel method for electroretinogram assessment in patients with central retinal vein occlusion.

Authors:  Neda Sefandarmaz; Soroor Behbahani; Alireza Ramezani
Journal:  Doc Ophthalmol       Date:  2020-01-07       Impact factor: 2.379

Review 4.  Retinitis pigmentosa and other dystrophies.

Authors:  José Sahel; Sébastien Bonnel; Sarah Mrejen; Michel Paques
Journal:  Dev Ophthalmol       Date:  2010-08-10

5.  Abnormalities of the retinal cone system in retinitis pigmentosa.

Authors:  D C Hood; D G Birch
Journal:  Vision Res       Date:  1996-06       Impact factor: 1.886

6.  Inner retinal function in hereditary retinal dystrophies.

Authors:  K Ruether; U Kellner
Journal:  Acta Anat (Basel)       Date:  1998

Review 7.  Neuroprotective strategies for retinal disease.

Authors:  Machelle T Pardue; Rachael S Allen
Journal:  Prog Retin Eye Res       Date:  2018-02-23       Impact factor: 21.198

8.  Retinitis pigmentosa: a brief overview.

Authors:  S Natarajan
Journal:  Indian J Ophthalmol       Date:  2011 Sep-Oct       Impact factor: 1.848

Review 9.  Retinitis pigmentosa.

Authors:  Christian Hamel
Journal:  Orphanet J Rare Dis       Date:  2006-10-11       Impact factor: 4.123

10.  Chaotic analysis of the electroretinographic signal for diagnosis.

Authors:  Surya S Nair; K Paul Joseph
Journal:  Biomed Res Int       Date:  2014-06-15       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.